B007 not checked
Shanghai Jiaolian Drug Research and Development Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “B007 high dose and low dose: Subcutaneous injection was administered on days 1 and 15”In the company’s words, NCT06447597 on ClinicalTrials.gov
- Tested for
- Primary Membranous Nephropathy (2 trials), Generalized Myasthenia Gravis, Pemphigus
- Main trialPhase 2/3
- “The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.”In the company’s words, NCT06447597 on ClinicalTrials.gov
Other drugs for Primary Membranous Nephropathy
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- BaxdrostatAstraZeneca · Phase 3
- BelzutifanMerck & Co. · Phase 3
- AbexinostatXynomic Pharmaceuticals, Inc. · Phase 3
Coming up4
- 30 DecPhase 2/3 trial completes · ClinicalTrials.gov
- 30 DecPhase 1 trial completes · ClinicalTrials.gov
- 31 DecPhase 2/3 trial completes · ClinicalTrials.gov
- 31 DecPhase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 30 Dec 2026 | A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. | |
| Phase 2/3Recruiting | 31 Dec 2026 | A Clinical Study of B007 in the Treatment of Pemphigus. | |
| Phase 2/3Recruiting | 31 Dec 2026 | A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. | |
| Phase 1Recruiting | 30 Dec 2026 | A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026